Automate Your Wheel Strategy on AMGN
With Tiblio's Option Bot, you can configure your own wheel strategy including AMGN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol AMGN
- Rev/Share 63.4312
- Book/Share 11.5372
- PB 24.5762
- Debt/Equity 9.2446
- CurrentRatio 1.1704
- ROIC 0.0953
- MktCap 152461159240.0
- FreeCF/Share 20.2881
- PFCF 13.968
- PE 25.7112
- Debt/Assets 0.6421
- DivYield 0.0327
- ROE 0.9294
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | AMGN | Guggenheim | -- | Neutral | -- | $288 | May 20, 2025 |
| Resumed | AMGN | Cantor Fitzgerald | -- | Neutral | -- | $305 | April 22, 2025 |
| Resumed | AMGN | BofA Securities | -- | Underperform | -- | $256 | Dec. 10, 2024 |
| Initiation | AMGN | Bernstein | -- | Outperform | -- | $380 | Oct. 17, 2024 |
| Downgrade | AMGN | Truist | Buy | Hold | $320 | $333 | Oct. 14, 2024 |
| Initiation | AMGN | Cantor Fitzgerald | -- | Overweight | -- | $405 | Sept. 27, 2024 |
News
Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know
Published: May 27, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.
Read More
Avoid These Dividend Disasters Before It's Too Late
Published: May 23, 2025 by: Seeking Alpha
Sentiment: Negative
Dividend stocks are facing many big risks. The high interest rates, trade war, and AI revolution could lead to many dividend cuts. I discuss what this all means for dividend investors.
Read More
Amgen Inc. (AMGN) RBC Capital Markets Global Healthcare Conference (Transcript)
Published: May 21, 2025 by: Seeking Alpha
Sentiment: Neutral
Amgen Inc. (NASDAQ:AMGN ) RBC Capital Markets Global Healthcare Conference May 21, 2025 9:00 AM ET Company Participants Justin Claeys - VP, IR Kave Niksefat - Senior Vice President of Global Marketing & Access Conference Call Participants Gregory Renza - RBC Capital Markets Gregory Renza Good morning everyone. Welcome back to 2025 RBC Global Healthcare Conference.
Read More
AMGN Down 10% in 3 Months: How to Play the Stock as Tariff Woes Linger
Published: May 21, 2025 by: Zacks Investment Research
Sentiment: Neutral
AMGN's consistent top-line growth, an interesting pipeline and rising estimates are good enough reasons to stay invested in the stock for now.
Read More
Amgen vs Bristol Myers: Which Biotech Giant Has Better Prospects?
Published: May 19, 2025 by: Zacks Investment Research
Sentiment: Positive
At current levels, we believe AMGN scores above BMY, buoyed by solid fundamentals and recent positive estimate revisions.
Read More
Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock
Published: May 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.
Read More
Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet
Published: May 12, 2025 by: Seeking Alpha
Sentiment: Neutral
President Trump has announced today he plans to reduce U.S. drug prices by 30-80% via an Executive Order, targeting Big Pharma's high costs and profits. U.S. drug prices are significantly higher (up to ten time more in some cases) than in other countries due to, e.g., R&D costs, direct-to-consumer marketing, and pharmacy benefit managers. Despite Trump's aggressive stance, Pharma stocks have risen in trading today, suggesting investors believe negotiations will soften his initial hardline approach.
Read More
Pharma Stocks Hit by Trump's Vow to Cut US Prescription Drug Costs
Published: May 12, 2025 by: Zacks Investment Research
Sentiment: Negative
The price cuts would see that U.S. consumers pay the same amount as the nation that pays the lowest price for that drug.
Read More
Amgen CEO Robert A. Bradway to Receive Honorary Degree from KGI
Published: May 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
Claremont, CA, May 08, 2025 (GLOBE NEWSWIRE) -- During the Keck Graduate Institute commencement ceremony on May 17, 2025, Robert A. Bradway will receive an honorary Doctor of Philosophy in Applied Life Sciences degree in recognition of his significant leadership contributions to the biotechnology field.
Read More
Amgen's TEPEZZA®▼ (teprotumumab) Granted Marketing Authorisation as the First Targeted Treatment Specifically for Adults With Moderate-to-severe Thyroid Eye Disease (TED) in the United Kingdom
Published: May 07, 2025 by: Business Wire
Sentiment: Neutral
CAMBRIDGE, England--(BUSINESS WIRE)--Today, Amgen announced that the UK's Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for TEPEZZA® (teprotumumab) as the first therapy specifically licensed for the treatment of adult patients with moderate-to-severe Thyroid Eye Disease (TED). Affecting approximately 50,000 people in the UK,1 TED is a progressive and potentially vision-threatening condition, which can cause eye bulging, double vision, eye pain, r.
Read More
Here's Why Amgen (AMGN) is a Strong Growth Stock
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Here's Why Amgen (AMGN) is a Strong Value Stock
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Is Trending Stock Amgen Inc. (AMGN) a Buy Now?
Published: May 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.
Read More
AMGN's Key Drugs Repatha, Evenity & Blincyto Drive Q1 Sales Growth
Published: May 05, 2025 by: Zacks Investment Research
Sentiment: Positive
AMGN's 14 products, including Repatha, Blincyto, Tezspire, Tavneos and Evenity, achieve double-digit volume growth in the first quarter.
Read More
Beat the Nasdaq With This Cash-Gushing Dividend Stock
Published: May 01, 2025 by: The Motley Fool
Sentiment: Positive
Reliable dividend income from high-quality companies is a great option for investors seeking to ride out stock market turbulence. Biotech giant Amgen (AMGN 0.82%) exemplifies this strategy with its 3.3% dividend yield, supported by steady growth and rock-solid fundamentals.
Read More
Will Amgen (AMGN) Beat Estimates Again in Its Next Earnings Report?
Published: April 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
Will These 5 Big Drug Stocks Surpass Q1 Earnings Forecasts?
Published: April 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Let's look at five pharma and drug companies, PFE, LLY, AMGN, BIIB and REGN, which are scheduled to release their first-quarter 2025 results later this week.
Read More
4 Surefire Dividend Stocks to Buy in the Stock Market Sell-Off
Published: April 26, 2025 by: The Motley Fool
Sentiment: Positive
It's always a good time to buy solid dividend stocks, but considering the challenging economic environment, now might be a particularly opportune time. Dividend-paying companies tend to have strong underlying operations and are generally more resilient than their non-dividend-paying counterparts.
Read More
Amgen to expand Ohio biotech manufacturing plant
Published: April 25, 2025 by: Reuters
Sentiment: Positive
Amgen on Friday announced a $900 million expansion of its Ohio biotech manufacturing facility, becoming the latest in a string of drugmakers pledging to increase U.S. capacity amid Trump administration threats of potential import tariffs.
Read More
AMGEN ANNOUNCES $900 MILLION MANUFACTURING EXPANSION, CREATION OF 350 NEW JOBS IN OHIO
Published: April 25, 2025 by: PRNewsWire
Sentiment: Neutral
Total Investment in the State to Exceed $1.4 Billion, 750 U.S. Jobs THOUSAND OAKS, Calif. , April 25, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced a $900 million expansion of its Ohio manufacturing facility, bringing the total number of jobs created to 750 and the total investment in Central Ohio to over $1.4 billion.
Read More
3 Relatively Safe Healthcare Growth Stocks You Can Buy and Hold
Published: April 22, 2025 by: The Motley Fool
Sentiment: Positive
When the stock market is highly volatile, many investors flock to assets that offer stability but dismal growth prospects. However, you don't necessarily have to sacrifice growth for safety.
Read More
Final Trades: Take-Two Interactive, Franco-Nevada, Amgen and the 10-Year Treasury
Published: April 21, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee give you their top stocks to watch for the second half.
Read More
Here's Why Amgen (AMGN) is a Strong Value Stock
Published: April 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Trump Says Pharmaceutical Tariffs Coming in Near Future
Published: April 14, 2025 by: Bloomberg Markets and Finance
Sentiment: Negative
President Donald Trump said tariffs on pharmaceuticals will be coming in the “not too distant future” and fit in the category of tariffs imposed on cars, steel, and aluminum. Trump spoke with reporters Monday in the Oval Office.
Read More
Trump says US pharma tariffs coming in not-too-distant future
Published: April 14, 2025 by: Reuters
Sentiment: Negative
U.S. President Donald Trump said on Monday that he expects to impose tariffs on imported pharmaceuticals in the not-too-distant future.
Read More
Trump's pharmaceutical tariffs could raise costs for patients, worsen drug shortages
Published: April 11, 2025 by: CNBC
Sentiment: Negative
President Donald Trump's planned tariffs on pharmaceuticals imported into the U.S. could have wide-ranging consequences on the drug supply chain, manufacturers and American patients, some experts told CNBC. The tariffs could disrupt the complex pharmaceutical supply chain, potentially driving up the prices of drugs in the U.S. and exacerbating shortages of critical medicine.
Read More
IMDELLTRA® DEMONSTRATED SUPERIOR OVERALL SURVIVAL IN SMALL CELL LUNG CANCER
Published: April 11, 2025 by: PRNewsWire
Sentiment: Neutral
First Global Phase 3 Trial Showing Substantial Survival Advantage Over Chemotherapy, for Patients With Progression On or After Platinum-Based Chemotherapy THOUSAND OAKS, Calif. , April 11, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the global Phase 3 DeLLphi-304 clinical trial evaluating IMDELLTRA® (tarlatamab-dlle) as a treatment for patients with small cell lung cancer (SCLC) who progressed on or after a single line of platinum-based chemotherapy met its primary endpoint at a planned interim analysis.
Read More
Healthy Returns: Trump says major pharmaceutical tariffs coming ‘very shortly'
Published: April 09, 2025 by: CNBC
Sentiment: Negative
Trump doubled down on plans to soon impose "major" pharmaceutical tariffs, while early stage startups dominated digital health funding deals in first quarter.
Read More
Pharma Stocks Slide Further After Trump Reiterates Tariff Threats on Drugs
Published: April 09, 2025 by: WSJ
Sentiment: Negative
Drugmakers have said they're still unclear about whether Trump will impose tariffs on finished products or on active pharmaceutical ingredients.
Read More
Pharmaceutical stocks fall as Trump doubles down on tariffs threat
Published: April 09, 2025 by: CNBC
Sentiment: Negative
Pharmaceutical stocks fell after President Donald Trump doubled down on plans to impose tariffs on pharmaceuticals imported into the U.S. "very shortly." Shares of Eli Lilly, AbbVie, Bristol Myers Squibb, Regeneron, Merck, Pfizer, Johnson & Johnson and Amgen, among others, all dropped on Wednesday.
Read More
About Amgen Inc. (AMGN)
- IPO Date 1983-06-17
- Website https://www.amgen.com
- Industry Drug Manufacturers - General
- CEO Mr. Robert A. Bradway
- Employees 28000